AG
UBX

Artal Group’s Unity Biotechnology UBX Stock Holding History

Artal Group’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-5,000
Closed -$815K – 115
2018
Q3 		$815K Sell
5,000
-15,000
-75% -$2.47M 0.02% 102
2018
Q2 		$3.01M Buy
+20,000
New +$2.92M 0.06% 84

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PIM
Partner Investment Management San Francisco, California $13.9M AUM 55.92% 1-Year Est. Return

Artal Group's UBX Position: Q4 2018 in Review

Artal Group sold out of Unity Biotechnology (UBX) in Q4 2018, closing a stake of 5,000 shares — an estimated $815K sold.

Artal Group first reported a position in UBX in Q2 2018 and held it in 2 quarters. The position peaked at $3.01M in Q2 2018. 55 funds tracked by Wall St. Rank hold UBX as of Q4 2018.

  • Artal Group reported no remaining Unity Biotechnology position as of Q4 2018 after selling out during the quarter.
  • Artal Group sold 5,000 Unity Biotechnology shares in Q4 2018, an estimated $815K.
  • Artal Group first reported a position in Unity Biotechnology in Q2 2018 and held it in 2 quarters.
  • Artal Group's Unity Biotechnology position peaked at $3.01M in Q2 2018.
  • 55 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2018.

Based on Artal Group's 13F filing for Q4 2018, filed 11 Feb 2019.